SG Americas Securities’s Aldeyra Therapeutics ALDX Stock Holding History

SG Americas Securities’s Portfolio ALDX Stock Details ALDX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-12,000	Closed	-$62K	–	3188
2025 Q4	$62K	Buy	+12,000	New	+$61.6K	﹤0.01%	3322
2025 Q2	–	Sell	-17,818	Closed	-$102K	–	2899
2025 Q1	$102K	Sell	17,818 -4,547	-20%	-$26.9K	﹤0.01%	3029
2024 Q4	$112K	Buy	22,365 +2,822	+14%	+$14.5K	﹤0.01%	2646
2024 Q3	$105K	Buy	19,543 +8,165	+72%	+$38.9K	﹤0.01%	3025
2024 Q2	$38K	Buy	+11,378	New	+$44.6K	﹤0.01%	2717
2024 Q1	–	Sell	-11,028	Closed	-$39K	–	2942
2023 Q4	$39K	Buy	+11,028	New	+$34K	﹤0.01%	2956
2021 Q4	–	Sell	-17,348	Closed	-$152K	–	3349
2021 Q3	$152K	Buy	+17,348	New	+$159K	﹤0.01%	3425
2021 Q1	–	Sell	-26,578	Closed	-$182K	–	3250
2020 Q4	$182K	Buy	+26,578	New	+$187K	﹤0.01%	2681
2018 Q4	–	Sell	-94,269	Closed	-$1.3M	–	3035
2018 Q3	$1.3M	Buy	+94,269	New	+$765K	0.01%	1494

Other funds holding ALDX

KCM

Knoll Capital Management Miami, Florida $179M AUM 63.61% 1-Year Est. Return

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AQR Capital Management Greenwich, Connecticut $287B AUM 42.33% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

KCM

Kingdon Capital Management New York $976M AUM 66.76% 1-Year Est. Return

6CM

683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return

D.E. Shaw & Co New York $210B AUM 57.28% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Millennium Management New York $276B AUM 44.8% 1-Year Est. Return

SG Americas Securities's ALDX Position: Q1 2026 in Review

SG Americas Securities sold out of Aldeyra Therapeutics (ALDX) in Q1 2026, closing a stake of 12,000 shares — an estimated $62K sold.

SG Americas Securities first reported a position in ALDX in Q3 2018 and held it in 9 quarters. The position peaked at $1.3M in Q3 2018. 128 funds tracked by Wall St. Rank hold ALDX as of Q1 2026.

SG Americas Securities reported no remaining Aldeyra Therapeutics position as of Q1 2026 after selling out during the quarter.
SG Americas Securities sold 12,000 Aldeyra Therapeutics shares in Q1 2026, an estimated $62K.
SG Americas Securities first reported a position in Aldeyra Therapeutics in Q3 2018 and held it in 9 quarters.
SG Americas Securities's Aldeyra Therapeutics position peaked at $1.3M in Q3 2018.
128 funds tracked by Wall St. Rank held Aldeyra Therapeutics as of Q1 2026.

Based on SG Americas Securities's 13F filing for Q1 2026, filed 16 Apr 2026.